TrialsgrambetaRCTs are beautiful

SENSCIS

2019

Nintedanib in Systemic Sclerosis-Associated ILD

In 576 patients with SSc-associated ILD, nintedanib slowed annual FVC decline compared with placebo.

Result

Primary endpoint: Annual rate of FVC decline

-52.4 vs -93.3 mL/year (44% reduction; p=0.04).

Original publication
Subtopic
SSc-ILD
Design
Multicentre RCT
Relevance
Supporting: context rather than must-know.
Source
Distler O, et al. N Engl J Med. 2019;380(26):2518-2528.doi 10.1056/NEJMoa1903076

Discussion & critique

Third FDA indication for nintedanib.